Overview

  • Product name

    Anti-TFPI antibody - C-terminal
    See all TFPI primary antibodies
  • Description

    Rabbit polyclonal to TFPI - C-terminal
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Rhesus monkey
  • Immunogen

    Synthetic peptide corresponding to Human TFPI aa 261-280 (C terminal).
    Sequence:

    QECLRACKKGFIQRISKGGL


    Database link: P10646-1

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage buffer

    Preservatives: 0.025% Thimerosal (merthiolate), 0.025% Sodium azide
    Constituents: 0.1% Dibasic monohydrogen sodium phosphate, 2.5% BSA, 0.45% Sodium chloride
  • Concentration information loading...
  • Purity

    Immunogen affinity purified
  • Clonality

    Polyclonal
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab190928 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.1 - 0.5 µg/ml. Predicted molecular weight: 35 kDa.
IHC-P Use a concentration of 0.5 - 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • Function

    Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.
  • Tissue specificity

    Mostly in endothelial cells.
  • Sequence similarities

    Contains 3 BPTI/Kunitz inhibitor domains.
  • Domain

    This inhibitor contains three inhibitory domains. The first domain interacts with VIIa and TF, the second one with Xa.
  • Post-translational
    modifications

    O-glycosylated.
  • Cellular localization

    Secreted.
  • Information by UniProt
  • Database links

  • Alternative names

    • Anti convertin antibody
    • EPI antibody
    • Extrinsic pathway inhibitor antibody
    • LACI antibody
    • Lipoprotein associated coagulation inhibitor antibody
    • Lipoprotein-associated coagulation inhibitor antibody
    • TFI antibody
    • TFPI 1 antibody
    • TFPI antibody
    • TFPI1 antibody
    • TFPI1_HUMAN antibody
    • Tissue factor pathway inhibitor (lipoprotein associated coagulation inhibitor) antibody
    • Tissue factor pathway inhibitor antibody
    see all

References

ab190928 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (MCF7, Breast Cancer Cell line)
Permeabilization
Yes - 75% Ethanol + 25% Acetic Acid
Specification
MCF7, Breast Cancer Cell line
Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: RT°C
Fixative
Paraformaldehyde

Mrs. Mackenzie Malo

Verified customer

Submitted Feb 29 2016

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up